Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Q3 FY2013 Earnings Presentation
10 slides from Immutep's earnings presentation, Apr 25, 2013
Slide 1: 3rd quarter results supplemental information (period ended 31 March 2013)
Exhibit 99.2 3rd quarter (period Supplemental April ASX:PRR; 1PRIMA24,ended BIOMED 2013 results NASDAQ:PBMD; information 31 March for FY2013) 2013 to management ISIN:US74154B2034 discussion
Slide 2: Important Notice and presentation announcements
Important presentation announcements The or expectations from plans, forecast 2P RIMA reliability purpose views assumptions expectations BIOMED byNotice expressed Prima aid of andthe made only beliefs BioMed. orinformation. presentation and expectations in and bybeliefs this about Prima theNothing p
Slide 3: Highlights of the 3rd Quarter
Highlights Start EUR -Departure Announced 3PAdditional RIMA Phase Manufacturing Continue of 3.82CANVAS BIOMED million pilot of of asSPP immune Neil the atrials consultant and optimization grant 3rd Frazer, trial in option monitoring Quarter to additional of support Chief CVac through entitlement pro
Slide 4: R&D Update: CAN-003 and CAN-004
R&D CAN-003: -CAN-004 4P RIMA Final 31 30 43 Seven cell clinical patients Update immune PFS patients BIOMED collection (CANVAS) upcoming and centers havemonitoring initial have consented centers activated data doses OS - controlled data for activated data confirmed; toand all in participate in 63 4t
Slide 5: Clinical Leadership Update - Two Strong Additions
Clinical -Two Strong 5P RIMA Holbrook Pamela new experience BIOMED Leadership Klein, consultants Kohrt, MDin MD, Update -immunotherapy added Founder PhDto- Instructor the & President clinical & biologics ofleadership Medicine, of PMK as BioResearch; well team Division as(announced oncology of Oncolo
Slide 6: Financial results and net cash
Financial Net Cash Projected A$ *according 6P RIMA 2.86 12.8 1.54 25.17 20 cash from &million term BIOMED million outflow results million loss R&D todeposits International forfor tax for FYthe incentive the first 2013: at Quarter end quarter: three Financial of&quarters quarter: ended grantReporting
Slide 7: Capital raising: Share Purchase Plan
Capital Share Closing Goal Details -For Eligible Price 7P RIMA 1300 +61 questions, to will 2purchase 737 announced raising 9290 raise date BIOMED shareholders be760 of the about 9600 contact -plan (within SPP: SPP 10-day (outside to A$open 10th ASX may BoardRoom: 15 Australia) VWAP to million of inv
Slide 8: Capital raising: Entitlement Offer of options
Capital Announced Details Plan Purchase Entitlement Purchased 8P RIMA to offer will raising BIOMED price options abe istoplanned not made planned -Australian Options transferable expected available options for Entitlement &A$ toNew entitlement in 0.02 trade aZealand prospectus per on ASX option offe
Slide 9: Extraordinary General Meeting request for directors
Extraordinary Directors EGM Request 9P RIMA announced BIOMED for would shareholder General like for 16th toMeeting participate approval of May to 2013 inallow SPP up a placement to their maximum to directors allowable of up toentitlement A$ 2 million of Prima shares at the same terms as the SPP in t
Slide 10: Use of funds
Use of funds Co-fund Continue Provide PRIMA 10 general BIOMED three CVacphase manufacturing working 2 trials capital of optimization CVac for the in additional Company to moveand cancer toward addindications security our goal toand of ouracontinue balance commercially sheet our ongoing successful cl